OnCo
trialsTrialPlanned

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

A phase 3 trial of Inetetamab, Sirolimus protein-bound particles and Pyrotinib in Breast cancer, run by Peking Union Medical College, not yet recruiting.